“ A Phase III, Randomized, Non-Inferiority Study Comparing the Efficacy and Safety of Biosimilar Filgrastim Versus Originator Filgrastim for Chemotherapy-Induced Neutropenia in Breast Cancer Patients ”. Clinics, vol. 71, no. 10, Oct. 2016, pp. 586-92, https://doi.org/10.6061/clinics/2016(10)06.